ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

SCYX vs GRCE // REVENUE GROWTH (YOY)

SCYNEXIS Inc. (NASDAQ) VS. Grace Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: SCYX 3 — GRCE 2
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SCYX VS. GRCE) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC SCYX GRCE SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -18.90% -16.10 GRCE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield -13.76% -21.73% +7.97 SCYX /fcf-yield <GO>
Operating Margin -60.00% — — TIE /operating-margins <GO>
Net Profit Margin -41.80% — — TIE /net-margins <GO>
Revenue Growth (YoY) ACTIVE 180.00% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 4/9 2/9 +2.00 SCYX /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 40.6 37.7 +2.90 SCYX /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $37.9M $38.1M -$167.0K GRCE /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR SCYX REV GRCE REV SCYX GROSS % GRCE GROSS % SCYX FCF GRCE FCF
FY 2025 $20.6M $31.0M — — -$5.3M -$8.9M
FY 2024 $3.7M $46.7M — — -$24.0M -$14.9M
FY 2023 $140.1M $36.0M — — $60.2M -$12.3M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SCYX // BETA —
GRCE // BETA —